학술논문

Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non-small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; JUN 1 2022, 40 16, 1p. Supplement: S
Subject
Language
English
ISSN
15277755